-
October 4, ASH Advocacy Webinar ASH News
-
October 5, Medicare Quarterly Updates Medicare News/Noridian Programs
-
October 5, Proposed OPPS Rule Medicare News/CMS News
-
COA meets with Republican House Oversight & Reform Committee members. COA News
-
NIH identifies 3 subtypes of lung cancers. NIH News
|
|
MOASC is pleased to announce that we have partnered with patient payments firm, PayGround to deliver an end to end patient collections platform for MOASC members. With their modern patient-first approach, MOASC predicts that members will increase their patient collections by 12%, decrease their overall days to collect by 4 days, all while saving 26% in processing fees. With this partnership, MOASC members not only get access to PayGround’s aggregated payment platform, but we negotiated that PayGround waive all processing fees for the first 90 days for members. MOASC plans to launch the partnership beginning in October followed by a November webinar to educate members on the benefits of using PayGround’s payment platform.
|
|
Never fight an insurance company again!
Impiricus is a new platform for Oncologists to access resources and get patients on therapy. Get access to grants, samples, information and more. Submit prior authorization and patient assistance requests in under 30 seconds with Impiricus’ digital interface. Impiricus does all the hard work, but keep you in the loop.
Free Figs and Medelita white coats when using the sign up code: MOASC
|
|
MOASC Programs - Save the Dates - All Times are Pacific
|
|
Reminder – On October 2, 2021, MOASC’s Spotlight On Clinical Oncology. MOASC Board member, Jason Zell, MD, UCI will moderate discussions on: Melanoma presented by Omid Hamid, MD; Genitourinary Cancer presented by Nataliya Mar, MD; Hepatobiliary presented by Jennifer Valerin, MD; Gastrointestinal Cancer presented by May T. Cho, MD; Lung Cancer presented by Misako Nagasaka, MD, and Breast Cancer presented by Ritesh Parajuli, M.D.
|
|
Targeted Oncology cordially invites MOASC Members to three upcoming virtual roundtables intended for oncologists treating Myeloproliferative neoplasms: Myelofibrosis and Polycythemia Vera and Relapsed/Refractory Multiple Myeloma. These Virtual Case-Based Roundtable Meetings are collaborative, small-group meetings designed around case-based clinical profiles and peer-dialogue led by an expert physician. These sessions offer practicing oncologists the perfect opportunity to sharpen their skills and expertise in treatment strategies. Attendees are paid $500 of compensation, per session, by Healthcare Research Analytics®, for their attendance, participation & completion of the post-event HRA survey.
|
|
Program 1: PARP Inhibition as Primary Maintenance Therapy for Advanced Ovarian Cancer Thursday, September 30th, 7-8:30pm PDT
|
|
Program 2: Myeloproliferative neoplasms: Myelofibrosis and Polycythemia vera is on Wednesday, October 6th, 7-8:30pm PDT.
|
|
Program 3: BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma is on Tuesday, October 19th, 7-8:30pm PDT.
|
|
October 29-30, the University of California San Diego invites you to their inaugural Delivering Discoveries: Updates in Oncology CME conference. The diagnosis and management of cancer patients is increasingly complex and requires multidisciplinary management. This 1.5 day event will address all aspects of cancer from basic science research, advances in clinical care, to community-based approaches that optimize prevention and interception.
|
|
November 4 and November 10, SAVE THE DATE for MOASC’S Annual Practice Management Series! The virtual Educational Series will be presented in two tracks.
Track one – Oncology Administration November 4 from 11:45am – 3:15pm
Topics include: How to deal with Employee Fatigue, Time Management and Process Automation for Practices.
Track two – Oncology Billing November 10 from 11:45am – 3:15pm
Topics include: 2022 Billing updates, Overview of Medicare Regulations, Positioning Your Physician Organization for Financial Success and How to Increase Revenue.
There will be opportunity for attendees to spend time Networking in the Zoom Room with our gracious Sponsors. Thank you, AstraZeneca, BeiGene, Bristol Myers Squibb, Grail, Inc., Oncopeptides, Pfizer Oncology, Takeda Oncology, AbbVie, Astellas, Daiichi Sakyo, Inc., Incyte, Johnson and Johnson, Merck, Novartis, ADC Therapeutics, Agios Pharmaceuticals, Exact Sciences, Foundation Medicine, Gilead, G1 Therapeutics, Guardant Health, Kite Pharma, Lilly Oncology, Morphosys, Inc., Myovant Sciences, Pharmacyclics, Sanofi-Genzyme, Seagen, Stemline Therapeutics, Coherus Biosciences, Rigel Pharmaceuticals, VerdePharm Health.
|
|
Career Board
-
Practice Administrator in the Arizona market is looking to relocate back to the Southern California area to be closer to family. She previously worked at a large Oncology Group in Glendale, CA prior to taking leadership roles at a few Oncology clinics in the Arizona market, including Ironwood Cancer. She has 22+ years of oncology experience. If interested, please contact the MOASC Office for more information at moasc@moasc.org.
|
|
On Oct. 7, 2021, Optum will start managing online requests for outpatient radiation oncology therapies. This applies to UnitedHealthcare Community Plan Medicaid members in:
California, Florida, Maryland, Mississippi, Ohio, Rhode Island, Washington, Wisconsin.
To help you navigate this new process, UHC is offering 1-hour training sessions to go over the:
Prior authorization request process and the online tool for submitting notification/prior authorization requests. The online tool will be open on Oct. 1, 2021, for prior authorization requests with a start date of Oct. 7, 2021, or later. After you register, you’ll receive a confirmation email with an option to add the training session to your calendar. Questions unitedoncology@uhc.com.
|
|
Western Colorectal Cancer Consortium Conference (WC4) – Now a VIRTUAL Event!
On October 14-15, 2021 the WC4 goals remain focused on how Covid-19 has disrupted access to the CRC care continuum in the western region, highlighting ways for screening programs to recover mid-pandemic, with many presenters focusing on health disparities and inequities, both pre- and mid-pandemic. The California Colorectal Cancer Coalition (C4) is very excited to share the expertise of their speakers and the abundance of interesting topics. The virtual format (Whova) allows for a robust engagement, allowing participants to navigate the conference venue at their choosing, similar to an in-person event, without the risk of Covid-19/Delta variant exposure for you and your loved ones. There will also be free AAFP CME (currently 13.25h, subject to change) available through your conference attendance.
|
|
Quarterly Medicare Updates - A/B Webinar - October 5, 2021. This event includes: CMS and Noridian Updates, October 2021 Quarterly Provider Updates, Change Requests (CR), Recurring Updates, Special Editions (SE), and Resources
|
|
Quarterly Medicare Updates - A/B - After Hours Webinar - October 14, 2021. This event includes: CMS and Noridian Updates, October 2021 Quarterly Provider Updates, Change Requests (CR), Recurring Updates, Special Editions (SE), and Resources.
|
|
Help CMS Improve Provider Resources by taking this confidential Medicare survey, asking about information and resources you use to understand the Medicare program and/or help you bill correctly. AIHC is an educational partner with CMS and asks you to take a few minutes to complete an important Medicare billing survey from CMS. The survey is part of a study CMS is conducting to help improve your experience with resources about the Medicare program and correct billing. Responses are confidential, and the survey should take about 10 minutes to complete. Please participate by sharing your thoughts.
|
|
October 5, 2021, 10am PDT, join Bobbi Buell for a free webinar on the Proposed Outpatient Prospective Payment System Rule which is slated to start January 1, 2022.
|
|
Beginning July 1, 2022, most group health plans and health insurance issuers will be required to publish provider-specific reimbursement rates in machine-readable files on the internet due to the Transparency in Coverage final rule.
|
|
In keeping with the American Cancer Society Cancer Action Network’s (ACS CAN) mission to ensure all Americans have access to cancer care from prevention through treatment, ACS CAN is undertaking an effort to better understand provider- and practice-level factors that may represent barriers to oncology providers utilizing appropriate biomarker testing across cancer types. This brief online survey will take no more than ten minutes of your time and is being conducted anonymously, so your responses will be used only in aggregate and cannot be attributed to you. There is no need to prepare in advance for the survey questions; only your opinion is sought. The survey will cover current use and practices regarding biomarker testing across cancer types, and seek to understand any challenges that may arise. The goal of this research is to support new opportunities to improve patient access to biomarker testing.
To thank you for your time, the first 300 qualified respondents will receive an Amazon gift card of $75 if you choose to share your contact information (to be used solely for the purpose of distributing the gift card). Please feel free to contact (Sarah.Long@cancer.org) if you have any questions. Thank you.
|
|
Affiliate Association News |
|
UC Davis is conducting a survey of Medical Oncologists. All interested medical oncologists are invited to participate in this survey about genetic counseling. You may win an iPad in the process! Please contact jachuynh@ucdavis.edu with any questions. Thank you.
ANCO's 2021 Professional Education Meeting is taking place virtually on October 27th.
|
|
ANCO's Hematologic Malignancies Updates (part III of III), will be November 6, 2021- Hyatt Regency San Francisco Embarcadero. The faculty will present the latest research on treatment modalities for hematologic malignancies—leukemias, lymphomas, and myeloma—along with case studies for these diagnoses. Registration deadline is Thursday, November 4th.
|
|
Four seats on the ANCO Board of Directors are up for election in 2021. ANCO seeks nominations for candidates to stand for election to these seats. This year's election will be conducted via election runner online in December. Candidates with the top four vote totals will serve for three years (i.e., from 2022-2024, inclusive). You may nominate an ANCO member (including yourself) to stand for election to the Board via e-mail to director@anco.org no later than November 15.
|
|
On October 4, 1-2pm PDT, ASH is hosting the final of their new series titled the ASH Advocacy Webinar Series, Working with Advocacy Groups and Coalitions: How to Amplify Your Voice in Washington. ASH is committed to educating its members on how to become effective advocates for hematology research and practice. Registration is free and open to all interested.
|
|
Advance registration for the 63rd ASH Annual Meeting & Exposition is well underway, and are counting down the days until we meet again! Don’t miss the premier event in hematology!
|
|
The ASCO Nominating Committee has selected 15 distinguished members as candidates for open leadership positions within the Society. This year’s diverse slate reflects significant innovations that were adopted by the membership to increase diversity and inclusivity in ASCO governance. Voting Members are urged to vote in the election beginning November 3, 2021. Voting will close on December 7, 2021.
|
|
ASCO has created a temporary online job board to help connect oncology trainees with positions of employment, in lieu of the in-person networking received at the ASCO Annual Meeting. Between September 16 and October 15, 2021, trainees can view the list of available jobs, seek out more info, and apply. If you are recruiting trainees for open positions at your organization, please fill out the form or forward it to your hiring department.
|
|
COA News
COA President, Kashyap Patel, MD, & COA Exec. Dir., Ted Okon, had a great live meeting last week on Capitol Hill with several Republican members that are on the House Oversight & Reform Committee, including the ranking member. They discussed PBM abuses from A to Z, heavily focused on DIR fees. They handed out a real CVS DIR practice report and defied anyone to figure it out. COA has a plan, and the legislators’ commitment, to force a hearing on PBM abuses, with a focus on DIR fees. Realistically, given logistics and the current infighting on infrastructure, the timing of such hearings are looking at 3 months or so to pull, with the ranking member Rep. Comer needing to work through the Democrat chair. All-in-all it was a very good, and productive meeting.
|
|
NIH News
Researchers at the NIH have identified three subtypes of lung cancers in people who never smoked. The results could help guide more precise lung cancer treatments.
|
|
Incyte announces FDA approval of Jakafi® (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. The FDA approval was based on the REACH3 study, a Phase 3, randomized, open-label, multicenter study of Jakafi in comparison to best available therapy (BAT) for treatment of steroid-refractory chronic GVHD after allogeneic stem cell transplantation. The primary endpoint of overall response rate (ORR) at Week 24 (i.e., Cycle 7 Day 1) was 49.7% for Jakafi compared to 25.6% for BAT (P<0.0001).
|
|
Novartis announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
